EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature

Alexandre Gaubert, Thibault Kervarrec, Henri Montaudié, Fanny Burel-Vandenbos, Nathalie Cardot-Leccia, Ilaria Di Mauro, Thibault Fabas, Anne Tallet, Valérie Kubiniek, Florence Pedeutour, Bérengère Dadone-Montaudié

Journal of Investigative Dermatology · 2023

DOI: 10.1016/j.jid.2023.01.014 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Investigative Dermatology, 2023. Verfasst von Alexandre Gaubert und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Oncology, Central Laboratory of Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Ni…. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine cancer. Management of advanced MCC is mainly based on immune-checkpoint inhibitors. The high failure rate warrants an investigation of new therapeutic targets. The recent identification of BRCA1 or BRCA2 (BRCA1/2) mutations in some MCC raises the issue of the use of poly-(ADP-Ribose)-polymerase inhibitors in selected advanced cases. The main objective of our study is to determine the accurate frequency of BRCA1/2 pathogenic variants. We studied a series of 30 MCC and performed a meta-analysis of BRCA1/2 variants of published cases in the literature. In our series, we detected only one BRCA2 pathogenic variant. The low frequency of BRCA1/2 pathogenic variants in our series of MCC (3%) was confirmed by the meta-analysis of BRCA1/2 variants in the literature. Among the 915 MCC from 13 published series studied for molecular alterations of BRCA1/2, only 12 BRCA1/2 pathogenic mutations were identified (1-2% of MCC), whereas many other BRCA1/2 variants were variants of unknown significance or benign. BRCA1/2 pathogenic variants are uncommon in MCC. However, in BRCA-mutated MCC, poly-(ADP-Ribose)-polymerase inhibitors might be a valuable therapeutic option requiring validation by clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellSkin NeoplasmsOvarian NeoplasmsHumansFemaleBRCA1 ProteinBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsAdenosine Diphosphate RiboseGerm-Line MutationGenetic Predisposition to Disease

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsAdenosine Diphosphate Ribose

Autor:innen und Institutionen

  • Department of Pathology and Molecular Oncology, Central Laboratory of Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
  • Biologie des infections à polyomavirus team, UMR INRA ISP 1282, University of Tours, Tours, France; Department of Pathology, Centre Hospitalier Universitaire de Tours, Tours, France.
  • INSERM U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Nice, France; Department of Dermatology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
  • Laboratory of Solid Tumor Genetics, Department of Pathology and Molecular Oncology, University Hospital of Nice, University Côte d'Azur, Nice, France; Laboratory of Solid Tumor Genetics, Institute for Research on Cancer…
  • Laboratory of Solid Tumor Genetics, Department of Pathology and Molecular Oncology, University Hospital of Nice, University Côte d'Azur, Nice, France.
  • Platform of Somatic Tumor Molecular Genetics, Université de Tours, Centre Hospitalier Universitaire de Tours, Tours, France.

Zitieren

APA

Gaubert, A., Kervarrec, T., Montaudié, H., Burel-Vandenbos, F., Cardot-Leccia, N., Di Mauro, I., Fabas, T., Tallet, A., Kubiniek, V., Pedeutour, F., & Dadone-Montaudié, B. (2023). BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2023.01.014

Vancouver

Gaubert A, Kervarrec T, Montaudié H, Burel-Vandenbos F, Cardot-Leccia N, Di Mauro I, et al. BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. Journal of Investigative Dermatology. 2023. doi:10.1016/j.jid.2023.01.014

BibTeX
@article{Gaubert2023,
  author = {Gaubert, Alexandre and Kervarrec, Thibault and Montaudié, Henri and Burel-Vandenbos, Fanny and Cardot-Leccia, Nathalie and Di Mauro, Ilaria and Fabas, Thibault and Tallet, Anne and Kubiniek, Valérie and Pedeutour, Florence and Dadone-Montaudié, Bérengère},
  title = {BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature},
  journal = {Journal of Investigative Dermatology},
  year = {2023},
  doi = {10.1016/j.jid.2023.01.014}
}
Kostenlos starten →